Sanofi to snap up Blue­print Med­i­cines and mas­to­cy­to­sis drug Ay­vak­it for $9.1B

In the biggest bio­phar­ma deal since Jan­u­ary, Sanofi is bol­ster­ing its rare im­munol­o­gy of­fer­ing by ac­quir­ing Blue­print Med­i­cines for $9.1 bil­lion.

The French drug­mak­er has …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER